Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 22, 2024
Reporting Period: This filing announces financial results for the three and twelve months ended December 31, 2023. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing does not contain specific comparative data or material changes versus prior periods. It solely references the issuance of a press release containing the results for the period ended December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on March 22, 2024, but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this text.
Legal Disclaimer: The information in Item 2.02 and the referenced press release is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 22, 2024) for actual financial figures, as they are not included in the 8-K text.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbols: Common stock (REVB) and Redeemable warrants (REVBW) on The Nasdaq Stock Market LLC.
- Note that the financial data referenced is not incorporated by reference into other SEC filings unless explicitly stated.